Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
& Schapira, A
Oral GLP-1s for obesity saw a recent setback when in April (April 2025), Pfizer announced that it was discontinuing development of danuglipron, an oral GLP-1 receptor agonist, which was being investigated for chronic weight management, due to potential liver toxicity
Efficacy and safety of glucagon-like Peptide-1 receptor agonists in the treatment of metabolic associated fatty liver disease: a systematic review and Meta-analysis
&srotate=0)
Bityutskiy LP, Soykan I, McCallum RW
US$ 21.36
US$ 25.21
US$ 29.83
US$ 22.30
US$ 23.08
US$ 25.32
US$ 21.47
